Key terms
About RCUS
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RCUS news
Feb 25
11:29pm ET
Evaluating Arcus Biosciences’ Casdatifan Potential and Strategic Position in RCC Treatment Landscape
Feb 22
7:11am ET
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR)
Feb 22
5:40am ET
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Ionis Pharmaceuticals (IONS) and Icon (ICLR)
Feb 22
5:07am ET
Barclays Sticks to Its Buy Rating for Arcus Biosciences (RCUS)
Feb 21
4:11pm ET
Arcus Biosciences reports Q4 EPS ($1.08), consensus ($1.02)
Feb 08
6:31am ET
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Arcus Biosciences (RCUS) and Neurocrine (NBIX)
Feb 02
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Feb 01
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 30
8:38am ET
Arcus Biosciences price target lowered to $30 from $36 at Wedbush
Jan 30
6:36am ET
Arcus Biosciences price target lowered to $42 from $51 at Mizuho
Jan 29
5:06pm ET
Gilead raises ownership stake in Arcus Biosciences to 33%, adds board seat
Jan 24
1:44am ET
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Arcus Biosciences (RCUS) and Zai Lab (ZLAB)
Jan 24
1:40am ET
Optimistic Buy Rating for Arcus Biosciences Amid Promising Clinical Data on Quemliclustat
Jan 23
4:04am ET
Analysts Offer Insights on Healthcare Companies: Citius Pharmaceuticals (CTXR), Arcus Biosciences (RCUS) and Masimo (MASI)
Jan 16
5:03pm ET
Arcus Biosciences announces ‘promising’ ARC-8 Phase 1b study data
Jan 07
5:44am ET
BTIG Remains a Buy on Arcus Biosciences (RCUS)
Jan 02
9:44am ET
BTIG Remains a Buy on Arcus Biosciences (RCUS)
Dec 31
5:23am ET
BTIG Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Dec 11
7:41pm ET
Analysts Conflicted on These Healthcare Names: Becton Dickinson (BDX), Arcus Biosciences (RCUS) and Keros Therapeutics (KROS)
Dec 07
3:09am ET
Buy Rating Affirmed for Arcus Biosciences Amid Strategic Collaboration and Promising Trial Milestones
Dec 04
8:28am ET
Exelixis, Arcus team on trial of zanzalintinib-AB521 combo to treat ccRCC
Dec 04
7:20am ET
Arcus Biosciences management to meet with Truist
No recent news articles are available for RCUS
No recent press releases are available for RCUS
RCUS Financials
Key terms
Ad Feedback
RCUS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RCUS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range